[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 20 of about 20
1. Saurez G, Cabanas R, Zaldívar M, Garnier T, Iglesias B, Piedra P, Castillo MR, Longchong M, Iznaga N, Lage A: Clinical experience with nimotuzumab in cuban pediatric patients with brain tumors, 2005 to 2007. MEDICC Rev; 2009 Jul;11(3):27-33
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical experience with nimotuzumab in cuban pediatric patients with brain tumors, 2005 to 2007.
  • Introduction Nimotuzumab, developed in Cuba, is a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR).
  • It has been evaluated in malignant brain tumors in adults and children, and shown to be therapeutically safe and effective in terms of increased survival and improved quality of life.
  • Objective Describe nimotuzumab's safety profile and clinical benefits in terms of disease control and survival in pediatric patients with progressive or recurrent primary brain tumors who were included in an expanded access program.
  • Between December 2005 and December 2007, 22 patients were included, all of whom had an histological and/or radiological diagnosis of progressive or recurrent primary brain tumor, classified as high-grade malignant glioblastoma (n=6), diffuse brain stem glioma (n=6), ependymoblastoma (n=5), low-grade glioma (n=4), or thalamic tumor (n=1); life expectancy of at least 4 weeks; and a Karnofsky or Lansky Performance Status score of ≥50.
  • Therapeutic protocols were followed for administration as monotherapy or in combination with chemotherapy and/or radiotherapy.
  • Results Nimotuzumab was well tolerated in all therapeutic modalities, even with prolonged exposure.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21483304.001).
  • [ISSN] 1555-7960
  • [Journal-full-title] MEDICC review
  • [ISO-abbreviation] MEDICC Rev
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Uchino M, Kitajima S, Miyazaki C, Shibata I, Miura M: Bilateral thalamic glioma--case report. Neurol Med Chir (Tokyo); 2002 Oct;42(10):443-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral thalamic glioma--case report.
  • A 35-year-old woman presented with a bilateral thalamic glioma manifesting as dysesthesia over the left side of the body and mental deterioration.
  • Radiotherapy and chemotherapy failed to arrest tumor growth.
  • Magnetic resonance imaging and clinical findings support the view that bilateral thalamic gliomas represent a distinct clinicopathologic entity among thalamic tumors.
  • [MeSH-major] Brain Neoplasms / pathology. Glioma / pathology. Thalamus / pathology
  • [MeSH-minor] Adult. Biopsy. Female. Humans. Magnetic Resonance Imaging. Personality Disorders / diagnosis. Personality Disorders / etiology. Stereotaxic Techniques

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12416569.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 15
  •  go-up   go-down


3. Nass R, Boyce L, Leventhal F, Levine B, Allen J, Maxfield C, Salsberg D, Sarno M, George A: Acquired aphasia in children after surgical resection of left-thalamic tumors. Dev Med Child Neurol; 2000 Sep;42(9):580-90
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acquired aphasia in children after surgical resection of left-thalamic tumors.
  • Five children (three males, two females; four right-, one left-handed; age range 6 to 14 years) who developed aphasia after gross-total excision of left predominantly thalamic tumors are reported.
  • In the months after surgery, three children improved while receiving radiation and/or chemotherapy, although none recovered completely.
  • Two patients with malignant tumors developed worsening aphasia when the tumor recurred, and later died.
  • The wide range of deficits in these children highlights the importance of the thalamus and other subcortical structures in developing cognition.
  • [MeSH-major] Aphasia / etiology. Brain Neoplasms / surgery. Postoperative Complications. Thalamic Diseases / surgery


Advertisement
4. Yamada K, Takeshima H, Sakurama T, Kuratsu J: Secondary cervical dystonia following stereotactic radiosurgery in a patient with thalamic glioma. Surg Neurol; 2007 Dec;68(6):665-70
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary cervical dystonia following stereotactic radiosurgery in a patient with thalamic glioma.
  • We report the first patient with secondary CD after stereotactic radiosurgery for thalamic glioma.
  • CASE DESCRIPTION: A 27-year-old woman complaining of headache and left motor weakness was found to have a thalamic tumor on the right side.
  • Histopathologically, tumor samples manifested features of anaplastic astrocytoma.
  • She underwent stereotactic radiosurgery in addition to the conventional radiation and chemotherapy.
  • Sixteen months postoperatively, the patient developed forced head tilting to the left side combined with chin lift.
  • Irregular-shaped lesion involving the thalamus, lenticular nuclei, midbrain, pons, and cerebellum was presented on magnetic resonance images.
  • Steroid therapy effectively diminished the lesion size, and her abnormal head posturing was gradually ameliorated (TWSTRS severity scale = 3).
  • [MeSH-major] Brain Neoplasms / surgery. Glioma / surgery. Postoperative Complications / etiology. Radiosurgery / adverse effects. Torticollis / etiology
  • [MeSH-minor] Adult. Female. Humans. Magnetic Resonance Imaging. Necrosis. Thalamus / pathology. Thalamus / surgery


5. Scrigni A, Nastri M, Rodríguez de Schiavi S, Czornyj L, Felice M, Mantese B: Leptomeningeal lymphoma in a child with acquired immune deficiency syndrome. Neuropediatrics; 2006 Jun;37(3):121-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a seven-year-old HIV-infected boy, in stage C3 of the disease, who developed non-Hodgkin lymphoma in the central nervous system with a leptomeningeal location.
  • The diagnosis was based on brain biopsy, immunophenotypic studies of B cells, and Epstein-Barr virus serology of the cerebrospinal fluid.
  • The boy was treated with intrathecal and systemic chemotherapy.
  • Fifteen months after diagnosis he had clinically improved, but he then relapsed with a thalamic tumor.
  • In the present article, we discuss diagnostic difficulties, evolution, treatment, and the association of this neoplasm with the Epstein-Barr virus.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Lymphoma, Non-Hodgkin / etiology. Meningeal Neoplasms / etiology


6. Hill MD, Mackenzie I, Mason WP: Radiation-induced glioma presenting as diffuse leptomeningeal gliomatosis: a case report. J Neurooncol; 2001 Nov;55(2):113-6
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • He later developed an enhancing thalamic tumor arising within the treatment field of a remotely irradiated pituitary adenoma.
  • Subsequent management included chemotherapy and further radiotherapy with transient response, before death from leptomeningeal and parenchymal tumor progression 16 months after diagnosis.
  • Our patient's course is novel in that symptomatic relief was achieved with CSF diversion and a combination of chemotherapy and focal radiation allowed prolonged survival.
  • [MeSH-major] Adenoma / radiotherapy. Glioma / diagnosis. Meningeal Neoplasms / diagnosis. Neoplasms, Radiation-Induced / diagnosis. Pituitary Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Cerebrospinal Fluid Shunts. Combined Modality Therapy. Fatal Outcome. Humans. Magnetic Resonance Imaging. Male

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 1986 Aug;19(2):247-51 [3748352.001]
  • [Cites] Br J Cancer. 1992 Dec;66(6):999-1004 [1457369.001]
  • [Cites] Cancer. 1993 Oct 1;72(7):2227-33 [8374881.001]
  • [Cites] Neurology. 1996 Jun;46(6):1760-2 [8649589.001]
  • [Cites] Cancer. 1991 Jan 15;67(2):392-7 [1845944.001]
  • [Cites] Can J Neurol Sci. 1985 Aug;12 (3):278-81 [4052890.001]
  • [Cites] Neurology. 1984 Dec;34(12):1611-5 [6390250.001]
  • [Cites] J Neuropathol Exp Neurol. 1951 Jan;10(1):16-29 [14804124.001]
  • [Cites] Neurosurgery. 1997 Feb;40(2):393-6 [9007876.001]
  • [Cites] Neurosurgery. 1985 Sep;17(3):436-45 [2995867.001]
  • [Cites] J Comput Assist Tomogr. 1993 Mar-Apr;17(2):317-20 [8454762.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1994;6(6):361-3 [7873481.001]
  • [Cites] J Neurooncol. 1993 Jan;15(1):45-9 [8455062.001]
  • [Cites] Cancer. 1948 May;1(1):3-29 [18867438.001]
  • [Cites] Rev Neurol (Paris). 1995 Mar;151(3):177-89 [7676154.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1994 Apr;57(4):471-3 [8163998.001]
  • [Cites] Neurosurgery. 1990 Oct;27(4):516-21; discussion 521-2 [2172859.001]
  • [Cites] BMJ. 1992 Jul 25;305(6847):253-4 [1392843.001]
  • [Cites] Ann Neurol. 1980 Dec;8(6):605-8 [6260012.001]
  • [Cites] J Neurosurg. 1989 Jul;71(1):77-82 [2661743.001]
  • (PMID = 11817701.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


7. Wagner S, Csatary CM, Gosztonyi G, Koch HC, Hartmann C, Peters O, Hernáiz-Driever P, Théallier-Janko A, Zintl F, Längler A, Wolff JE, Csatary LK: Combined treatment of pediatric high-grade glioma with the oncolytic viral strain MTH-68/H and oral valproic acid. APMIS; 2006 Oct;114(10):731-43
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined treatment of pediatric high-grade glioma with the oncolytic viral strain MTH-68/H and oral valproic acid.
  • The case of a 12-year-old boy with anaplastic astrocytoma of the left thalamus is reported.
  • Postoperative irradiation and chemotherapy could not repress tumor progression; therefore, treatment was undertaken with an oncolytic virus, MTH-68/H, an attenuated strain of Newcastle disease virus (NDV), and valproic acid (VPA), an antiepileptic drug, which also has antineoplastic properties.
  • This treatment resulted in a far-reaching regression of the thalamic glioma, but 4 months later a new tumor manifestation, an extension of the thalamic tumor, appeared in the wall of the IVth ventricle, which required a second neurosurgical intervention.
  • Under continuous MTH-68/H - VPA administration the thalamic tumor remained under control, but the rhombencephalic one progressed relentlessly and led to the fatal outcome.
  • In the final stage, a third tumor manifestation appeared in the left temporal lobe.
  • The possible reasons for the antagonistic behavior of the three manifestations of the same type of glioma to the initially most successful therapy are discussed.
  • The comparative histological study of the thalamic and rhombencephalic tumor manifestations revealed that MTH-68/H treatment induces, similar to in vitro observations, a massive apoptotic tumor cell decline.
  • In the rhombencephalic tumor, in and around the declining tumor cells, NDV antigen could be demonstrated immunohistochemically, and virus particles have been found in the cytoplasm of tumor cells at electron microscopic investigation.
  • These findings document that the oncolytic effect of MTH-68/H treatment is the direct consequence of virus presence and replication in the neoplastic cells.
  • [MeSH-major] Anticonvulsants / therapeutic use. Astrocytoma / drug therapy. Astrocytoma / therapy. Brain Neoplasms / therapy. Valproic Acid / therapeutic use. Viral Vaccines / therapeutic use
  • [MeSH-minor] Administration, Oral. Antigens, Viral / analysis. Antigens, Viral / metabolism. Brain / virology. Child. Combined Modality Therapy. Cytoplasm / virology. Fatal Outcome. Humans. Male. Newcastle disease virus / immunology. Recurrence. Thalamus / pathology

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. VALPROIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17004977.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Anticonvulsants; 0 / Antigens, Viral; 0 / Newcastle disease virus vaccine MTH-68-H; 0 / Viral Vaccines; 614OI1Z5WI / Valproic Acid
  •  go-up   go-down


8. Lustig RH, Post SR, Srivannaboon K, Rose SR, Danish RK, Burghen GA, Xiong X, Wu S, Merchant TE: Risk factors for the development of obesity in children surviving brain tumors. J Clin Endocrinol Metab; 2003 Feb;88(2):611-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors for the development of obesity in children surviving brain tumors.
  • Hypothalamic obesity, a syndrome of intractable weight gain due to hypothalamic damage, is an uncommon but devastating complication for children surviving brain tumors.
  • We undertook a retrospective evaluation of the body mass index (BMI) curves for the St. Jude Children's Research Hospital brain tumor population diagnosed between 1965 and 1995 after completion of therapy to determine risk factors for the development of obesity.
  • Inclusion criteria were: diagnosis less than 14 yr of age, no spinal cord involvement, ambulatory, no supraphysiologic hydrocortisone therapy (>12 mg/m(2) x d), treatment and follow-up at St. Jude Children's Research Hospital, and disease-free survival greater than 5 yr (n = 148).
  • Risk factors examined were age at diagnosis, tumor location, histology, extent of surgery, hydrocephalus requiring ventriculoperitoneal shunting, initial high-dose glucocorticoids, cranial radiation therapy, radiation dosimetry to the hypothalamus, intrathecal chemotherapy, and presence of endocrinopathy.
  • Risk factors were: age at diagnosis (P = 0.04), radiation dosimetry to the hypothalamus (51-72 Gy, P = 0.002 even after hypothalamic and thalamic tumor exclusion), and presence of any endocrinopathy (P = 0.03).
  • In addition, risk factors when compared with BMI slope for the general American pediatric population included: tumor location (hypothalamic, P = 0.001), tumor histology (craniopharyngioma, P = 0.009; pilocytic astrocytoma, P = 0.043; medulloblastoma, P = 0.039); and extent of surgery (biopsy, P = 0.03; subtotal resection, P = 0.018).
  • These results verify hypothalamic damage, either due to tumor, surgery, or radiation, as the primary cause of obesity in survivors of childhood brain tumors.
  • In particular, hypothalamic radiation doses of more than 51 Gy are permissive.
  • These results reiterate the importance of the hypothalamus in energy balance, provide risk assessment criteria for preventative measures before the development of obesity in at-risk patients, and suggest therapeutic strategies to reduce the future development of obesity.
  • [MeSH-major] Brain Neoplasms / epidemiology. Craniopharyngioma / epidemiology. Obesity / epidemiology
  • [MeSH-minor] Astrocytoma / drug therapy. Astrocytoma / epidemiology. Astrocytoma / radiotherapy. Cerebellar Neoplasms / drug therapy. Cerebellar Neoplasms / epidemiology. Cerebellar Neoplasms / radiotherapy. Child. Child, Preschool. Disease-Free Survival. Humans. Hypothalamus / physiology. Medulloblastoma / drug therapy. Medulloblastoma / epidemiology. Medulloblastoma / radiotherapy. Retrospective Studies. Risk Factors

  • Genetic Alliance. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Obesity in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12574189.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R25 CA023944; United States / NCI NIH HHS / CA / P30CA12765
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


9. Reddy AT, Janss AJ, Phillips PC, Weiss HL, Packer RJ: Outcome for children with supratentorial primitive neuroectodermal tumors treated with surgery, radiation, and chemotherapy. Cancer; 2000 May 1;88(9):2189-93
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome for children with supratentorial primitive neuroectodermal tumors treated with surgery, radiation, and chemotherapy.
  • BACKGROUND: The outcome of a child with a primitive neuroectodermal tumors arising supratentorially (SPNET) is not well characterized and may differ from the outcome of a patient with a histologically similar cerebellar tumor (medulloblastoma [MB]).
  • Recently, 5-year progression free survival rates as high as 80% have been reported for children with MB treated with craniospinal radiation (CRT) and chemotherapy including cisplatin, lomustine (CCNU), and vincristine (VCR).
  • Tumor location included was 13 pineal, 6 cortical, and 3 thalamic or suprasellar.
  • Five patients had disease dissemination at diagnosis.
  • All patients underwent surgery and staging, followed by CRT and chemotherapy with cisplatin, CCNU, and VCR.
  • RESULTS: Of the 22 patients, 13 had developed disease progression and 10 had died at the time of last follow-up.
  • There was no statistical association between tumor location and survival.
  • CONCLUSIONS: The results of the current study demonstrate that the outcome for children with SPNET treated with radiation and chemotherapy appears worse than for children with MB treated with identical therapy.
  • This suggests that there may be biologic differences between supratentorial and infratentorial primitive neuroectodermal tumors, thus requiring refinements in treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cranial Irradiation. Neuroectodermal Tumors, Primitive / surgery. Supratentorial Neoplasms / surgery
  • [MeSH-minor] Adolescent. Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Cerebral Cortex / drug effects. Cerebral Cortex / radiation effects. Cerebral Cortex / surgery. Child. Child, Preschool. Cisplatin / administration & dosage. Disease Progression. Disease-Free Survival. Follow-Up Studies. Humans. Linear Models. Lomustine / administration & dosage. Neoplasm Staging. Pinealoma / drug therapy. Pinealoma / radiotherapy. Pinealoma / surgery. Retrospective Studies. Survival Rate. Thalamic Diseases / drug therapy. Thalamic Diseases / radiotherapy. Thalamic Diseases / surgery. Treatment Outcome. Vincristine / administration & dosage

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10813733.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


10. Allen JC: Initial management of children with hypothalamic and thalamic tumors and the modifying role of neurofibromatosis-1. Pediatr Neurosurg; 2000 Mar;32(3):154-62
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Initial management of children with hypothalamic and thalamic tumors and the modifying role of neurofibromatosis-1.
  • Optic pathway/hypothalamus gliomas (OPG) arise primarily from a slower-growing juvenile pilocytic astrocytoma, and thalamic gliomas arise primarily from a fibrillary astrocytoma which can become clinically and histologically more aggressive.
  • The major therapeutic challenge for these patients is to maximize their quality of life by preserving visual and endocrine function while minimizing treatment-related morbidity.
  • Treatment is often initiated at diagnosis in infants and toddlers who have a major visual impairment or the diencephalic syndrome.
  • The judicious application of chemotherapy may serve to forestall the need for radiotherapy or surgery.
  • Tumors may grow more slowly or occasionally regress spontaneously.
  • However, over 90% of children with OPG without NF-1 will require some form of therapy.
  • Patients with thalamic gliomas present with a shorter history, often with hydrocephalus.
  • Surgical intervention is often required to relieve intracranial pressure and establish the histologic identity of the tumor.
  • Over 75% of these tumors will become locally aggressive.
  • Current multimodality therapy is relatively ineffective.
  • [MeSH-major] Astrocytoma / surgery. Brain Neoplasms / surgery. Hypothalamic Neoplasms / surgery. Neurofibromatosis 1 / surgery. Thalamic Diseases / surgery
  • [MeSH-minor] Child. Child, Preschool. Humans. Hypothalamus / pathology. Infant. Magnetic Resonance Imaging. Neoadjuvant Therapy. Optic Nerve Glioma / diagnosis. Optic Nerve Glioma / surgery. Thalamus / pathology

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 S. Karger AG, Basel
  • (PMID = 10867564.001).
  • [ISSN] 1016-2291
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 21
  •  go-up   go-down


11. Siffert J, Allen JC: Late effects of therapy of thalamic and hypothalamic tumors in childhood: vascular, neurobehavioral and neoplastic. Pediatr Neurosurg; 2000 Aug;33(2):105-11
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late effects of therapy of thalamic and hypothalamic tumors in childhood: vascular, neurobehavioral and neoplastic.
  • The late effects in children with hypothalamic and thalamic tumors relate to the effects of the tumor on the surrounding brain, the effects of surgery, radiotherapy (RT) and, to a lesser extent, chemotherapy.
  • The prevention of late effects is an integral part of current treatment strategies.
  • Early diagnosis, a rational use of surgery, and deferral of RT are the mainstays of the modern treatment in these patients.
  • The improvement of RT techniques and the use of radioprotective compounds may further help spare normal brain tissue.
  • A better understanding of chemotherapy use and the development of newer agents may increase efficacy, reduce side effects and allow deferral of RT in a greater percentage of patients.
  • [MeSH-major] Brain Neoplasms / pathology. Brain Neoplasms / radiotherapy. Glioma / pathology. Hypothalamus / pathology. Hypothalamus / radiation effects. Neoplasms, Radiation-Induced / pathology. Thalamus / pathology. Thalamus / radiation effects. Visual Pathways / pathology. Visual Pathways / radiation effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 S. Karger AG, Basel.
  • (PMID = 11070438.001).
  • [ISSN] 1016-2291
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


12. Moshel YA, Link MJ, Kelly PJ: Stereotactic volumetric resection of thalamic pilocytic astrocytomas. Neurosurgery; 2007 Jul;61(1):66-75; discussion 75
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stereotactic volumetric resection of thalamic pilocytic astrocytomas.
  • OBJECTIVE: To describe the surgical approaches, the radiographic and clinical outcomes, and the long-term follow-up of patients harboring thalamic pilocytic astrocytomas after radical resection by means of a stereotactic volumetric technique.
  • METHODS: Seventy-two patients with thalamic pilocytic astrocytomas underwent stereotactic volumetric resection by the senior author (PJK) at the Mayo Clinic between 1984 and 1993 (44 patients) and at New York University Medical Center between 1993 and 2005 (28 patients).
  • Postoperative imaging demonstrated gross total resection in 58 patients and minimal (<6 mm) residual tumor in 13 patients.
  • Tumor resection was aborted in one patient.
  • After 13 to 20 years of follow-up in the Mayo group (mean, 15 +/- 3 yr) and 1 to 13 years of follow-up in the New York University group (mean, 8 +/- 3 yr), 67 patients were recurrence/progression-free, one had tumor recurrence, and three had progression of residual tumor.
  • CONCLUSION: Gross total removal of thalamic pilocytic astrocytomas with low morbidity and mortality can be achieved by computer-assisted stereotactic volumetric resection techniques.
  • Gross total resection of these lesions confers a favorable long-term prognosis without adjuvant chemotherapy and/or radiation therapy and leads to the improvement of neurological deficits.
  • [MeSH-major] Astrocytoma / surgery. Brain Neoplasms / surgery. Paresis / prevention & control. Stereotaxic Techniques. Thalamic Diseases / surgery. Thalamus / surgery
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17621020.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Moshel YA, Elliott RE, Monoky DJ, Wisoff JH: Role of diffusion tensor imaging in resection of thalamic juvenile pilocytic astrocytoma. J Neurosurg Pediatr; 2009 Dec;4(6):495-505
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of diffusion tensor imaging in resection of thalamic juvenile pilocytic astrocytoma.
  • OBJECT: The choice of surgical approach during resection of a thalamic juvenile pilocytic astrocytoma (JPA) is dictated by the location of the displaced normal thalamus and posterior limb of the internal capsule (PLIC).
  • Diffusion tensor (DT) imaging and white matter tractography can identify the location of the PLIC in relation to the tumor and may be useful in planning the operative trajectory.
  • METHODS: Diffusion tensor imaging was used to localize the PLIC on preoperative MR imaging in 6 children undergoing resection of thalamic JPAs.
  • This result was compared with the location of the PLIC determined by a blinded radiologist with the use of DT imaging.
  • The utility of DT imaging in determining the surgical approach to a thalamic JPA, degree of resection, and neurological outcomes were all evaluated.
  • Gross-total resection of all cystic and solid tumor components was confirmed on postoperative imaging in all cases.
  • CONCLUSIONS: Diffusion tensor imaging and white matter tractography successfully identified the white matter fibers emanating from the precentral gyrus within the PLIC in children with thalamic JPAs prior to surgery.
  • Diffusion tensor imaging served as a valuable tool for stereotactic planning of operative approaches to thalamic JPAs.
  • [MeSH-major] Astrocytoma / pathology. Astrocytoma / surgery. Brain Neoplasms / diagnosis. Brain Neoplasms / surgery. Diffusion Tensor Imaging / standards. Microsurgery. Thalamus / pathology. Thalamus / surgery


14. Iwami K, Arima T, Ooka F, Asai T, Tambara M, Takaoka T: [Bilateral thalamic glioma in an adult: a case report and review of the literature]. No Shinkei Geka; 2009 Mar;37(3):285-90
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bilateral thalamic glioma in an adult: a case report and review of the literature].
  • We report a case of a 36-year-old woman who had a rare bilateral thalamic glioma (BTG).
  • BTG is a rare variant of thalamic neoplasms, which can be distinguished clinically and radiologically from other gliomas.
  • Death usually occurs within two years after onset, independently of adjuvant therapy such as radiotherapy and chemotherapy.
  • At the time of this writing (5 months after the consultation), there are no neurological symptoms, and no changes on neuroimaging.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Thalamus

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19306649.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 16
  •  go-up   go-down


15. Walter AW, Gajjar A, Reardon DA, Thompson SJ, Langston JW, Jones-Wallace D, Kun LE, Heideman RL: Tamoxifen and carboplatin for children with low-grade gliomas: a pilot study at St. Jude Children's Research Hospital. J Pediatr Hematol Oncol; 2000 May-Jun;22(3):247-51
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The authors conducted a single-arm, prospective study using tamoxifen and carboplatin for the treatment of children with progressive or symptomatic low-grade gliomas.
  • One patient was excluded after induction chemotherapy because of the diagnosis of a nonmalignant condition.
  • RESULTS: The median age at diagnosis was 5.3 years, the median age at initiation of chemotherapy was 8.3 years.
  • Eight patients had tumors of the hypothalamus/optic pathway, two patients had thalamic tumors, and one patient each had tumors in the temporal lobe, tectum, and brain stem.
  • Tumor histologic findings included fibrillary astrocytoma (n = 2), juvenile pilocytic astrocytoma (n = 6), and oligodendroglioma (n = 1).
  • The best response to therapy was a partial response in two patients, stable disease in nine patients, and progressive disease in two patients.
  • Tamoxifen and carboplatin chemotherapy did not result in a significant number of objective responses in children with low-grade gliomas.
  • Nonmyelosuppressive agents such as tamoxifen deserve additional evaluation in the treatment of children with low-grade gliomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Oligodendroglioma / drug therapy
  • [MeSH-minor] Carboplatin / administration & dosage. Child. Child, Preschool. Disease Progression. Disease-Free Survival. Enzyme Inhibitors / administration & dosage. Female. Humans. Life Tables. Male. Prospective Studies. Protein Kinase C / antagonists & inhibitors. Survival Analysis. Survival Rate. Tamoxifen / administration & dosage. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10864056.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA-20180; United States / NCI NIH HHS / CA / P01 CA-23099; United States / NCI NIH HHS / CA / P30 CA-21765
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 094ZI81Y45 / Tamoxifen; BG3F62OND5 / Carboplatin; EC 2.7.11.13 / Protein Kinase C
  •  go-up   go-down


16. Buhl R, Stark AM, Hugo HH, Rohr A, Mehdorn HM: Gliosarcoma: clinical experiences and additional information with MR spectroscopy. Neurol Res; 2009 Oct;31(8):873-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Six tumors were in the frontal lobe, four in the temporal lobe, three parietal, two in the thalamic area and one in the occipital lobe.
  • Median survival time in our patient group was 7 months (2-11 months).
  • On histological examination, we found glial fibrillary acid protein positive cells surrounded by sarcomatous tissue and reticular fibers.
  • MR spectroscopy and location of the tumor adjacent to the dura with inhomogeneous contrast enhancement might give hints pre-operatively for the differential diagnosis of gliosarcoma.
  • Further works with adjuvant chemotherapy are necessary.
  • [MeSH-major] Brain / pathology. Brain Neoplasms / pathology. Gliosarcoma / pathology
  • [MeSH-minor] Aged. Cell Proliferation. Diagnosis, Differential. Female. Glial Fibrillary Acidic Protein / metabolism. Humans. Magnetic Resonance Spectroscopy. Male. Middle Aged. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Gliosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19215667.001).
  • [ISSN] 0161-6412
  • [Journal-full-title] Neurological research
  • [ISO-abbreviation] Neurol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein
  •  go-up   go-down


17. Darmoul M, Habib Bouhaouala M, Smida H, Hedi Dougui M: [Pseudo-tumoral neuro-Behçet's disease]. Rev Neurol (Paris); 2006 May;162(5):643-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neuroradiological investigations showed a pseudo tumoral lesion in the left capsulo-thalamic region extending to the homolateral peduncle.
  • The patient improved with steroid and immunosuppresseur therapy.
  • CONCLUSION: The clinical and radiological presentation of neuro-Behçet's disease can mimic a brain tumor.
  • [MeSH-major] Behcet Syndrome / diagnosis. Brain Diseases / diagnosis
  • [MeSH-minor] Administration, Oral. Adult. Anti-Inflammatory Agents / administration & dosage. Aphasia / etiology. Brain Neoplasms / diagnosis. Consciousness Disorders / diagnosis. Cyclophosphamide / administration & dosage. Dominance, Cerebral / physiology. Drug Therapy, Combination. Headache / etiology. Hemiplegia / etiology. Humans. Immunosuppressive Agents / administration & dosage. Internal Capsule / pathology. Magnetic Resonance Imaging. Male. Mesencephalon / pathology. Methylprednisolone / administration & dosage. Thalamus / pathology

  • Genetic Alliance. consumer health - Behcet's Disease.
  • MedlinePlus Health Information. consumer health - Behcet's Syndrome.
  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16710132.001).
  • [ISSN] 0035-3787
  • [Journal-full-title] Revue neurologique
  • [ISO-abbreviation] Rev. Neurol. (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Immunosuppressive Agents; 8N3DW7272P / Cyclophosphamide; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


18. Klein O, Grignon Y, Civit T, Pinelli C, Auque J, Marchal JC: [Childhood diencephalic pilocytic astrocytoma. A review of seven observations]. Neurochirurgie; 2006 Feb;52(1):3-14
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND PURPOSE: Pilocytic astrocytoma (PA) is a WHO grade I tumor of the central nervous system mostly arising in children and young adults.
  • Surgical treatment has to cope with both the difficulties of deep location and eloquent area tumors.
  • Opto-chiasmatic tumors were excluded from the series.
  • Mean age at diagnosis was 108 months (9 years) (range: 4 month-18 years), median age was 111 months.
  • Tumor locations were as followed: right thalamus: 2, both thalami: 1, hypothalamus: 3, and right basal ganglia: 1.
  • The delay in diagnosis ranged from 48 hours up to 6 years.
  • TREATMENT: a shunting procedure was performed in 3 patients, a direct surgical approach in 5 patients (gross total removal: 2; partial removal: 3) and one patient had only a biopsy.
  • Chemotherapy was delivered for 4 children.
  • Three children died, two by tumor progression and one death related to late side-effects of RT.
  • We observed tumor regression in two patients at 1 and 17 years after the beginning of treatment.
  • Correct diagnosis was only made for two cases at the initial pathological examination.
  • The tumor can be controlled by a partial surgical removal, and a residual tumor can sometimes decrease in size after surgery.
  • Gross total removal of these tumors, although difficult, may be performed.
  • Pathological diagnosis is sometimes difficult to assess.
  • [MeSH-major] Astrocytoma / surgery. Brain Neoplasms / surgery. Hypothalamic Neoplasms / surgery. Thalamic Diseases / surgery
  • [MeSH-minor] Adolescent. Chemotherapy, Adjuvant. Child. Child, Preschool. Combined Modality Therapy. Dominance, Cerebral / physiology. Female. Follow-Up Studies. Humans. Hypothalamus / pathology. Hypothalamus / surgery. Infant. Magnetic Resonance Imaging. Male. Quality of Life. Radiotherapy, Adjuvant. Reoperation. Retrospective Studies. Survival Rate. Thalamus / pathology. Thalamus / surgery. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16609655.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


19. Kaltsas GA, Powles TB, Evanson J, Plowman PN, Drinkwater JE, Jenkins PJ, Monson JP, Besser GM, Grossman AB: Hypothalamo-pituitary abnormalities in adult patients with langerhans cell histiocytosis: clinical, endocrinological, and radiological features and response to treatment. J Clin Endocrinol Metab; 2000 Apr;85(4):1370-6
Genetic Alliance. consumer health - Langerhans cell histiocytosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypothalamo-pituitary abnormalities in adult patients with langerhans cell histiocytosis: clinical, endocrinological, and radiological features and response to treatment.
  • We have evaluated the frequency and progression of LCH-related anterior pituitary and other NEH dysfunction and their responses to treatment in 12 adult patients with histologically proven LCH and DI.
  • They were followed up for a median of 11.5 yr (range, 3-28 yr) after the diagnosis of DI was made.
  • Study evaluations comprised clinical (including formal psychometric assessment where appropriate), basal and dynamic pituitary function tests, and radiology with computed tomography and/or magnetic resonance imaging scanning.
  • Eleven patients received systemic treatment, and 5 patients received external beam radiotherapy confined to the HPA.
  • The median age at diagnosis of DI was 34 yr (range, 2-47 yr); DI was the presenting symptom in four patients, whereas the remaining eight each developed DI 1-20 yr (median, 2 yr) after the diagnosis of LCH.
  • Eight patients developed one or more anterior pituitary hormonal deficiencies at a median of 4.5 yr (range, 2-22 yr) after the diagnosis of DI: GH deficiency developed in eight patients (median, 2 yr; range, 2-22 yr), FSH-LH deficiency in 7 patients (median, 7 yr; range, 2-22 yr), and TSH and ACTH deficiency in five patients (median, 10 yr; range, 3-16 and 3-19 yr), respectively; five patients developed panhypopituitarism.
  • In addition, seven patients with anterior pituitary dysfunction also developed symptoms of other NEH dysfunctions at a median of 10 yr (range, 1-23 yr): five morbid obesity (body mass index, >35), five short term memory deficits, four sleeping disorders, two disorders of thermoregulation, and one adipsia.
  • All patients developed disease outside of the hypothalamus during the course of the study, and no fluctuation of disease activity in the HPA region was noted.
  • Radiological examination of the HPA was abnormal in each of the eight patients with anterior pituitary involvement and in the seven patients with NEH dysfunction (one or more abnormalities): seven had thickening of the infundibulum, and one had hypothalamic and thalamic signal changes.
  • The five patients who received radiotherapy to the HPA achieved a partial or complete radiological response, and there was no evidence of tumor progression in this region.
  • No form of therapy, including chemotherapy, improved any established hormonal deficiencies or symptoms of NEH.
  • In summary, in our adult patients with hypothalamic LCH and DI, anterior pituitary hormonal deficiencies developed in 8 of 12 patients; these occurred over the course of 20 yr.
  • In addition, symptoms of NEH dysfunction developed in up to 90% of such patients and complicated management.
  • Radiotherapy may be useful in achieving local control of tumor, but established anterior, posterior pituitary, and other NEH dysfunctions do not improve in response to current treatment protocols.
  • [MeSH-major] Histiocytosis, Langerhans-Cell / physiopathology. Histiocytosis, Langerhans-Cell / therapy. Hypothalamus / physiopathology. Pituitary Gland / physiopathology
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / therapeutic use. Bone Diseases / etiology. Child, Preschool. Diabetes Insipidus / diagnosis. Diabetes Insipidus / etiology. Female. Humans. Hypopituitarism / etiology. Hypothalamic Diseases / etiology. Magnetic Resonance Imaging. Male. Middle Aged. Pituitary Hormones, Anterior / deficiency. Radiotherapy. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Histiocytosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10770168.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Pituitary Hormones, Anterior
  •  go-up   go-down


20. Arai M, Kashihara K, Kaizaki Y, Taguchi M, Kitamura Y: [Gliomatosis cerebri: report of 3 cases and review of recent literatures]. No To Shinkei; 2003 Oct;55(10):890-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gliomatosis cerebri is a rare tumor of the central nervous system characterized by widespread diffuse infiltration of the brain and spinal cord by neoplastic glial cells.
  • The diagnosis of gliomatosis cerebri with MR imaging remains difficult.
  • Case 1 showed transformation from type 1 gliomatosis cerebri to type 2.
  • Case 2 showed that the initial thalamic lesion extended into brain stem, cerebellar hemisphere and right cerebral hemisphere.
  • After radiation therapy, the right cerebral cortex demonstrated hyperintensity on T1- and hypointensity on T2-weighted image.
  • Case 3 improved in response to radiotherapy and chemotherapy using procarbazine/MCNU/vincristine (MVP).
  • [MeSH-major] Brain Neoplasms / diagnosis. Neoplasms, Neuroepithelial / diagnosis
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain / pathology. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Procarbazine / administration & dosage. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Gliomatosis Cerebri.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14635518.001).
  • [ISSN] 0006-8969
  • [Journal-full-title] Nō to shinkei = Brain and nerve
  • [ISO-abbreviation] No To Shinkei
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine
  • [Number-of-references] 11
  •  go-up   go-down






Advertisement